DBS improved the Parkinson's Disease symptom score by 25% in comparison to no treatment, including resting and action tremor by over 85%, and bradykinesia by 23%. It did not stop deterioration in speech, walking, and postural instability, including falling and freezing. L-dopa dosages reduced to about 63% of what they were initially. Daily living activity also improved. Dyskinesia and motor fluctuation scores also remained significantly lower. Potential adverse events included : a trend to weight loss, visual hallucinations, impulse control disorders possibly related to dopamine agonists, progressive cognitive decline culminating in dementia,  device related infections. For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.